文献速递血栓与止血

致病性脂质结合抗磷脂抗体与COVID-19严重程度相关

Pathogenic lipid-binding antiphospholipid antibodies are associated with severity of COVID-19.
PubMed 文献 · J Thromb Haemost · 2021-07-22

该研究分析住院COVID-19患者中脂质结合抗磷脂抗体(aPL)的存在及其与疾病严重程度的关系。两个队列(53例和121例)显示,脂质结合aPL在COVID-19中常见,且与更高的C反应蛋白和D-二聚体中位浓度、危重临床病程及致命结局相关。机制上,aPL靶向LBPA-EPCR复合物诱导单核细胞和内皮细胞的促血栓和炎症反应,并加速小鼠血栓形成。

要点

  • 脂质结合aPL在住院COVID-19患者中常见,与炎症和凝血标志物升高相关。
  • 脂质结合aPL阳性患者更易出现危重临床病程和致命结局。
  • aPL通过靶向LBPA-EPCR复合物诱导促血栓和炎症反应,或参与COVID-19相关凝血病。

核心结论

  • COVID-19患者快速扩增分泌致病性脂质结合aPL的B1a细胞,具有广泛血栓和炎症效应。
  • 脂质结合aPL与炎症和凝血标志物、临床严重程度及死亡率相关,提示aPL在COVID-19相关凝血病中可能起因果作用。

研究设计与样本

  • 单中心两个队列(53例和121例)住院的PCR确诊SARS-CoV-2感染患者,分析aPL存在与COVID-19临床严重程度。

主要发现

  • 脂质结合aPL在COVID-19中常见。
  • 脂质结合aPL阳性患者有更高的C反应蛋白和D-二聚体中位浓度。
  • 脂质结合aPL阳性患者更易有危重临床病程和致命结局。
  • 从COVID-19患者分离的脂质结合aPL靶向LBPA与EPCR的细胞表面复合物,诱导单核细胞和内皮细胞促血栓和炎症反应。
  • COVID-19患者血液中存在产生脂质反应性IgG型aPL的B1a细胞。

临床怎么用

  • 住院COVID-19患者中检测脂质结合aPL可能有助于识别血栓和炎症高风险患者。
  • 针对aPL或EPCR-LBPA通路的干预或可为COVID-19相关凝血病提供治疗思路。

局限性

  • 研究为单中心两个队列,样本量有限(53例和121例)。
  • aPL与COVID-19临床病程的关联需进一步验证因果性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Coronavirus disease 19 (COVID-19)-associated coagulopathy is a hallmark of disease severity and poor prognosis. The key manifestations of this prothrombotic syndrome-microvascular thrombosis, stroke, and venous and pulmonary clots-are also observed in severe and catastrophic antiphospholipid syndrome. Antiphospholipid antibodies (aPL) are detectable in COVID-19 patients, but their association with the clinical course of COVID-19 remains unproven. OBJECTIVES: To analyze the presence and relevance of lipid-binding aPL in hospitalized COVID-19 patients. METHODS: Two cohorts of 53 and 121 patients from a single center hospitalized for PCR-proven severe acute respiratory syndrome-coronavirus 2 infection were analyzed for the presence of aPL and clinical severity of COVID-19. RESULTS: We here demonstrate that lipid-binding aPL are common in COVID-19. COVID-19 patients with lipid-binding aPL have higher median concentrations of C-reactive protein and D-dimer, and are more likely to have a critical clinical course and fatal outcome. Lipid-binding aPL isolated from COVID-19 patients target the recently described cell surface complex of lysobisphosphatidic acid (LBPA) with the protein C receptor (EPCR) to induce prothrombotic and inflammatory responses in monocytes and endothelial cells. We show that B1a cells producing lipid-reactive aPL of the IgG isotype circulate in the blood of COVID-19 patients. In vivo, COVID-19 aPL accelerate thrombus formation in an experimental mouse model dependent on the recently delineated signaling pathway involving EPCR-LBPA. CONCLUSIONS: COVID-19 patients rapidly expand B1a cells secreting pathogenic lipid-binding aPL with broad thrombotic and inflammatory effects. The association with markers of inflammation and coagulation, clinical severity, and mortality suggests a causal role of aPL in COVID-19-associated coagulopathy.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Hollerbach A, Müller-Calleja N, Pedrosa D, et al. Pathogenic lipid-binding antiphospholipid antibodies are associated with severity of COVID-19. J Thromb Haemost. 2021. PMID: 34242469. doi:10.1111/jth.15455

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。